Ghassan K Abou-Alfa

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine
    Ghassan K Abou-Alfa
    Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Clin Oncol 34:321-5. 2011
  2. pmc A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Internal Medicine, Weill Medical College at Cornell University, New York, NY, United States Electronic address
    J Hepatol 60:319-24. 2014
  3. pmc Postoperative outcomes following pancreaticoduodenectomy: how should age affect clinical practice?
    Walid Faraj
    Liver Transplantation and Hepatopancreaticobiliary Surgery, Department of General Surgery, American University of Beirut, Cairo Street, Beirut 1107 2020, Lebanon
    World J Surg Oncol 11:131. 2013
  4. pmc Lymph-node ratio is an independent prognostic factor in patients with stage III colorectal cancer: a retrospective study from the Middle East
    Elias Elias
    Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Riad El Solh, Beirut, 1107 2020, Lebanon
    World J Surg Oncol 10:63. 2012
  5. ncbi request reprint c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival
    Celina Su Ping Ang
    Weill Medical College at Cornell University, Department of Medicine, New York, NY, USA
    Anticancer Res 33:3241-5. 2013
  6. doi request reprint The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
    Ghassan K Abou-Alfa
    Section of Gastrointestinal Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lancet Oncol 14:e283-8. 2013
  7. doi request reprint Shaping the future management of hepatocellular carcinoma
    Ghassan Abou-Alfa
    Department of Medicine, Memorial Sloan Kettering Medical Center, Weill Medical College at Cornell University, New York, New York 10065, USA
    Semin Liver Dis 33:S20-3. 2013
  8. ncbi request reprint Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial
    Ghassan K Abou-Alfa
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    JAMA 304:2154-60. 2010
  9. doi request reprint PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Chemother Pharmacol 68:539-45. 2011
  10. ncbi request reprint A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Am J Clin Oncol 28:334-9. 2005

Collaborators

Detail Information

Publications31

  1. doi request reprint Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine
    Ghassan K Abou-Alfa
    Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Clin Oncol 34:321-5. 2011
    ..The objective of this study was to assess the safety and efficacy of immunizing patients with resected pancreatic cancer with a vaccine targeted against their tumor-specific K-ras mutation...
  2. pmc A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Internal Medicine, Weill Medical College at Cornell University, New York, NY, United States Electronic address
    J Hepatol 60:319-24. 2014
    ..IGF-IR is implicated in hepatic carcinogenesis. This and preliminary evidence of biological activity of anti-IGF-1R monoclonal antibody cixutumumab in phase I trials prompted this phase II study...
  3. pmc Postoperative outcomes following pancreaticoduodenectomy: how should age affect clinical practice?
    Walid Faraj
    Liver Transplantation and Hepatopancreaticobiliary Surgery, Department of General Surgery, American University of Beirut, Cairo Street, Beirut 1107 2020, Lebanon
    World J Surg Oncol 11:131. 2013
    ..There are conflicting data regarding the safety of pancreatic resection in older patients. Potentially modifiable perioperative risk factors to improve outcomes in older patients have yet to be determined...
  4. pmc Lymph-node ratio is an independent prognostic factor in patients with stage III colorectal cancer: a retrospective study from the Middle East
    Elias Elias
    Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Riad El Solh, Beirut, 1107 2020, Lebanon
    World J Surg Oncol 10:63. 2012
    ..Our paper is the first analysis, to our knowledge, to deal with such data from the Middle East...
  5. ncbi request reprint c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival
    Celina Su Ping Ang
    Weill Medical College at Cornell University, Department of Medicine, New York, NY, USA
    Anticancer Res 33:3241-5. 2013
    ..We assessed c-MET and HGF expression in 49 patients with early-stage HCC and correlated the results with disease characteristics and survival...
  6. doi request reprint The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
    Ghassan K Abou-Alfa
    Section of Gastrointestinal Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lancet Oncol 14:e283-8. 2013
    ....
  7. doi request reprint Shaping the future management of hepatocellular carcinoma
    Ghassan Abou-Alfa
    Department of Medicine, Memorial Sloan Kettering Medical Center, Weill Medical College at Cornell University, New York, New York 10065, USA
    Semin Liver Dis 33:S20-3. 2013
    ....
  8. ncbi request reprint Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial
    Ghassan K Abou-Alfa
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    JAMA 304:2154-60. 2010
    ..The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial...
  9. doi request reprint PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Chemother Pharmacol 68:539-45. 2011
    ..Hepatocellular carcinoma (HCC) displays extensive hypoxia and expresses AKR1C3. This study evaluated the safety and efficacy of PR-104 plus sorafenib in HCC...
  10. ncbi request reprint A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Am J Clin Oncol 28:334-9. 2005
    ..A multicenter phase II study to determine the antitumor activity of exatecan was conducted in patients with advanced cholangiocarcinoma and gallbladder carcinoma...
  11. ncbi request reprint Selection of patients with hepatocellular carcinoma for sorafenib
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    J Natl Compr Canc Netw 7:397-403. 2009
    ..This article addresses these questions on the use of sorafenib in HCC, both in the locally advanced and metastatic settings, in addition to the potential future applications and uses of sorafenib...
  12. pmc Hepatocellular carcinoma: molecular biology and therapy
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 33:S79-83. 2006
    ....
  13. ncbi request reprint Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
    J Clin Oncol 24:4441-7. 2006
    ..A multicenter, randomized, phase III trial comparing exatecan plus gemcitabine versus gemcitabine alone in advanced pancreatic cancer was conducted...
  14. ncbi request reprint The impact of new data in the treatment of advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10022, USA
    Curr Oncol Rep 10:199-205. 2008
    ....
  15. ncbi request reprint Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, York, NY 10022, USA
    J Clin Oncol 24:4293-300. 2006
    ..This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, and biomarkers in advanced hepatocellular carcinoma (HCC) patients...
  16. doi request reprint Targeted agents and systemic therapy in hepatocellular carcinoma
    Celina Ang
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Recent Results Cancer Res 190:225-46. 2013
    ..Several pathways are now implicated in hepatocarcinogenesis and agents that target these pathways continue to be developed...
  17. pmc Advanced hepatocellular carcinoma: which staging systems best predict prognosis?
    Fidel David Huitzil-Melendez
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 28:2889-95. 2010
    ..Many staging systems that include both aspects have been developed. It remains unknown, however, which of these systems is optimal for predicting patient survival...
  18. ncbi request reprint A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma
    Eileen M Oʼreilly
    Gastrointestinal Oncology Service Department of Medicine Hepatopancreaticobiliary Surgery Service Gastroenterology and Nutrition Service Departments of Epidemiology and Biostatistics Pathology Radiology Surgery and Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY
    Ann Surg 260:142-8. 2014
    ..The role for neoadjuvant systemic therapy in resectable pancreas adenocarcinoma remains undefined...
  19. doi request reprint Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer
    Elizabeth Smyth
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Gastrointest Cancer 42:46-9. 2011
    ..Gastric cancer is the third most common cancer worldwide and the second leading cause of cancer deaths. Appropriate staging and treatment options relate to the stage of disease and performance status of the patient...
  20. pmc A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603)
    Eileen M O'Reilly
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncologist 15:1310-9. 2010
    ..gov identifier, NCT00397787). The primary endpoint was to determine the disease control rate (DCR) as measured by the Response Evaluation Criteria in Solid Tumors (complete response, partial response [PR], and stable disease) at 6 weeks...
  21. ncbi request reprint Pancreatic islet cell carcinoma presenting with concurrent Cushing's and Zollinger-Ellison syndromes: case series and literature review
    Rabih Said
    Staten Island University Hospital, New York, USA
    Eur J Gastroenterol Hepatol 22:246-52. 2010
    ..As the data confers a worse prognosis versus other pancreatic neuroendocrine tumors, the relatively favorable outcome of the two patients reported herein may reflect the impact of multiple therapeutic modalities...
  22. doi request reprint Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection
    Itaru Endo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 248:84-96. 2008
    ..This study analyzes changes in IHC frequency, demographics, and treatment outcome in a consecutive and single institutional cohort...
  23. ncbi request reprint Cytotoxic therapy for advanced pancreatic adenocarcinoma
    Eileen M O'Reilly
    Department of Medicine, Gastrointestinal Oncology Solid Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 34:347-53. 2007
    ..This underscores the major therapeutic hurdles that we have to surmount in this most challenging of human malignancies...
  24. doi request reprint Gastrointestinal cancer educational case series: management of metastatic adenocarcinoma of unknown primary origin in a Ph+ ALL survivor
    Celina Ang
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Gastrointest Cancer 42:165-70. 2011
    ..The workup and management of a carcinoma of unknown primary must consider the patient's clinical presentation, radiologic and pathologic findings, and comorbidities...
  25. doi request reprint Indications for neoadjuvant, adjuvant, and palliative chemotherapy in the treatment of biliary tract cancers
    Fidel David Huitzil-Melendez
    Section of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10022, USA
    Surg Oncol Clin N Am 18:361-79, x. 2009
    ..This article reviews the available evidence to support indications of systemic chemotherapy in the palliative setting and discuss the attempts to study it in the perioperative settings...
  26. doi request reprint A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients
    Andrew S Epstein
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Palliat Med 16:623-31. 2013
    ..Cardiopulmonary resuscitation (CPR) is an important advance directive (AD) topic in patients with progressive cancer; however such discussions are challenging...
  27. doi request reprint An update on clinical trials in the treatment of advanced hepatocellular carcinoma
    Jean K Lee
    Memorial Sloan Kettering Cancer Center, Cornell University, New York, NY 10065, USA
    J Clin Gastroenterol 47:S16-9. 2013
    ..Thus, there is a critical need for novel therapeutic approaches for the treatment of advanced HCC, and thus a clear justification for the already reported, currently ongoing, and planned clinical trials...
  28. ncbi request reprint New agents in hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Adv Hematol Oncol 6:423-4. 2008
  29. doi request reprint MicroRNA, hypoxic stress and hepatocellular carcinoma: Future directions
    Celina Ang
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Gastroenterol Hepatol 26:1586-8. 2011
    ..See article in J. Gastroenterol. Hepatol. 2011; 26: 1630-1637...
  30. pmc Current management of advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, New York, NY
    Gastrointest Cancer Res 2:64-70. 2008
    ..The innovative therapeutic outcomes associated with novel targeted therapies illustrates the need for biologic and pharmacokinetic end points to define their optimal doses and therapeutic effects...
  31. doi request reprint Expanding the treatment options for hepatocellular carcinoma: combining transarterial chemoembolization with radiofrequency ablation
    Andrew X Zhu
    JAMA 299:1716-8. 2008